Acute Myocardial Infarction (AMI)NCT07042321
Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients
An observational study of Acute Myocardial Infarction (AMI), run by The Third Xiangya Hospital of Central South University at 1 site in China.
Trial summary
The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction (AMI)
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2024to 31 Aug 2025
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with acute myocardial infarction
Who may be able to join
- Age ≥ 18 years.
- STEMI symptom onset time < 12 hours.
- STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias.
- Very high-risk NSTEMI; undergoing emergency PCI treatment.
- Voluntary signed informed consent form.
Who cannot join
- Non-obstructive acute myocardial infarction.
- Severe chronic kidney disease (defined as estimated glomerular filtration rate <20 mL/min per 1.73 m²).
- Pregnant women or those planning to become pregnant.
- Failure of emergency PCI.
- Unclear CMR images
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xiangya Third Hospital of Central South University
Changsha, Hunan Province,China, 410013
灿 Zhu Can, +8613348674820, zhucan1021@163.com
About this study
Official title: Triglyceride Glucol Index for Predicting the Value of No-Reflow in Patients Undergoing Emergency PCI for Acute Myocardial Infarction
The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. The study will enroll approximately 300 AMI patients treated at Xiangya Third Hospital of Central South University from June 2024 to August 2025. The main questions it aims to answer are:
- How does the TyG index correlate with the early detection of MVO?
- What differences in cardiovascular adverse events during hospitalization exist between groups with varying TyG index levels? Participants will undergo emergency PCI and CMR imaging within 3-7 days post-procedure. Data collected will include demographic characteristics, clinical history, coronary angiography data, laboratory test indicators (especially metabolic markers such as blood glucose and lipids), IVUS-related plaque information, and CMR results.
- Conditions
- Acute Myocardial Infarction (AMI)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| High TYG Index Group | Not described | |
| Medium TYG Index Group | Not described | |
| Low TYG Index Group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The presence or absence of microvascular obstruction (MVO) diagnosed by cardiac magnetic resonance (CMR) within 3-7 days postoperatively
Measured: 3-7 days postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2025
- Study start1 Jun 2024
- Primary completion31 Aug 2025 (estimated)
- Study completion31 Aug 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- More trials run by The Third Xiangya Hospital of Central South UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yu Cao, The Third Xiangya Hospital of Central South University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07042321
- Sponsor's protocol ID
- cy25231
- Status last verified
- Jun 2025
- First submitted
- 28 May 2025
- Last updated
- 2 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The nature of the data collected in this study includes sensitive information that is closely tied to the identity of the participants. Out of respect for the privacy and confidentiality of our participants, and in strict adherence to the terms of the informed consent they provided, we are unable to share individual participant data. We believe that protecting the privacy of our participants is of utmost importance, and we are committed to upholding these ethical standards throughout our research.
Publications
Kim MK, Ahn CW, Kang S, Nam JS, Kim KR, Park JS. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. Cardiovasc Diabetol. 2017 Aug 23;16(1):108. doi: 10.1186/s12933-017-0589-4.
PubMed 28830471Soeda T, Higuma T, Abe N, Yamada M, Yokoyama H, Shibutani S, Ong DS, Vergallo R, Minami Y, Lee H, Okumura K, Jang IK. Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture. Eur Heart J Cardiovasc Imaging. 2017 Jan;18(1):103-110. doi: 10.1093/ehjci/jev341. Epub 2016 Jan 22.
PubMed 26800769Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62. doi: 10.1016/S0140-6736(05)67402-8. No abstract available.
PubMed 16182882
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Triglyceride Glucol Index for Predicting the Value of No-Reflow in Patients Undergoing Emergency PCI for Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT07042321
- Acronym / sponsor ID
- cy25231
- Conditions
- Acute Myocardial Infarction (AMI)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- The Third Xiangya Hospital of Central South UniversityUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 31 Aug 2025 (estimated)
- Study completion
- 31 Aug 2025 (estimated)
- First posted
- 29 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. The study will enroll approximately 300 AMI patients treated at Xiangya Third Hospital of Central South University from June 2024 to August 2025. The main questions it aims to answer are:
- How does the TyG index correlate with the early detection of MVO?
- What differences in cardiovascular adverse events during hospitalization exist between groups with varying TyG index levels? Participants will undergo emergency PCI and CMR imaging within 3-7 days post-procedure. Data collected will include demographic characteristics, clinical history, coronary angiography data, laboratory test indicators (especially metabolic markers such as blood glucose and lipids), IVUS-related plaque information, and CMR results.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Month
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| High TYG Index Group | – | – |
| Medium TYG Index Group | – | – |
| Low TYG Index Group | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with acute myocardial infarction
Key inclusion criteria (5 listed)
- Age ≥ 18 years.
- STEMI symptom onset time < 12 hours.
- STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias.
- Very high-risk NSTEMI; undergoing emergency PCI treatment.
- Voluntary signed informed consent form.
Key exclusion criteria (5 listed)
- Non-obstructive acute myocardial infarction.
- Severe chronic kidney disease (defined as estimated glomerular filtration rate <20 mL/min per 1.73 m²).
- Pregnant women or those planning to become pregnant.
- Failure of emergency PCI.
- Unclear CMR images
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The presence or absence of microvascular obstruction (MVO) diagnosed by cardiac magnetic resonance (CMR) within 3-7 days postoperatively
Time frame: 3-7 days postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2025.
- Results publication: PubMed 28830471Kim MK, Ahn CW, Kang S, Nam JS, Kim KR, Park JS. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. Cardiovasc Diabetol. 2017 Aug 23;16(1):108. doi: 10.1186/s12933-017-0589-4.
- Results publication: PubMed 26800769Soeda T, Higuma T, Abe N, Yamada M, Yokoyama H, Shibutani S, Ong DS, Vergallo R, Minami Y, Lee H, Okumura K, Jang IK. Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture. Eur Heart J Cardiovasc Imaging. 2017 Jan;18(1):103-110. doi: 10.1093/ehjci/jev341. Epub 2016 Jan 22.
- Results publication: PubMed 16182882Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62. doi: 10.1016/S0140-6736(05)67402-8. No abstract available.
- Individual participant dataSharing planned: No. The nature of the data collected in this study includes sensitive information that is closely tied to the identity of the participants. Out of respect for the privacy and confidentiality of our participants, and in strict adherence to the terms of the informed consent they provided, we are unable to share individual participant data. We believe that protecting the privacy of our participants is of utmost importance, and we are committed to upholding these ethical standards throughout our research.
Related trials for Acute Myocardial Infarction (AMI)
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
Not yet recruitingObservational study
iLITE, Clinical Performance of the Angiolite™ Drug-Eluting Stent
PCI Patients, de Novo Coronary Lesions
Recruiting
SPIKE FLOW Endocardial Lead Safety and Performance Study
Acute Myocardial Infarction (AMI), Asystole
RecruitingObservational study
Trends and Risk Factors of Adverse Cardiovascular and Cerebrovascular Events After Primary PCI
Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
Recruiting
TMS for Sympathetic Hyperactivity and Inflammation in Acute Myocardial Infarction
Acute Myocardial Infarction (AMI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction (AMI), run by The Third Xiangya Hospital of Central South University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact can Zhu Can (+8613348674820, zhucan1021@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The presence or absence of microvascular obstruction (MVO) diagnosed by cardiac magnetic resonance (CMR) within 3-7 days postoperatively (time frame: 3-7 days postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07042321, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2025; AzTrials last refreshed its copy on 6 Nov 2026.